Cited by

• Histopathology of BCG and thiotepa treated bladders.

  Guinan P, Shaw M, Ray V. Guinan P, et al. Urol Res. 1986;14(4):211-5. doi: 10.1007/BF00441116. Urol Res. 1986. PMID: 3097901
• The effects of intravesical and intradermal application of a new B.C.G. on the dog bladder.

  vd Meijden AP, Steerenberg PA, de Jong WH, Bogman MJ, Feitz WF, Hendriks BT, Debruyne FM, Ruitenberg EJ. vd Meijden AP, et al. Urol Res. 1986;14(4):207-10. doi: 10.1007/BF00441115. Urol Res. 1986. PMID: 3787886
• Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial.

  Klein WR, Bras GE, Misdorp W, Steerenberg PA, de Jong WH, Tiesjema RH, Kersjes AW, Ruitenberg EJ. Klein WR, et al. Cancer Immunol Immunother. 1986;21(2):133-40. doi: 10.1007/BF00199861. Cancer Immunol Immunother. 1986. PMID: 3633215 Free PMC article.
• Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy.

  Klein WR, Steerenberg PA, Poelma F, vd Wiel E, Rutten VP, Misdorp W, de Jong WH, Ruitenberg EJ. Klein WR, et al. Cancer Immunol Immunother. 1986;22(2):87-94. doi: 10.1007/BF00199120. Cancer Immunol Immunother. 1986. PMID: 3719596 Free PMC article.
• Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

  de Jong WH, Steerenberg PA, Kreeftenberg JG, Tiesjema RH, Kruizinga W, van Noorle Jansen LM, Ruitenberg EJ. de Jong WH, et al. Cancer Immunol Immunother. 1984;17(1):18-27. doi: 10.1007/BF00205492. Cancer Immunol Immunother. 1984. PMID: 6563941 Free PMC article.